...
首页> 外文期刊>The Journal of Allergy and Clinical Immunology >Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease
【24h】

Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease

机译:哮喘和慢性阻塞性肺疾病患者的糖皮质激素抵抗

获取原文
获取原文并翻译 | 示例
           

摘要

Reduced responsiveness to the anti-inflammatory effects of corticosteroids is a major barrier to effective management of asthma in smokers and patients with severe asthma and in the majority of patients with chronic obstructive pulmonary disease (COPD). The molecular mechanisms leading to steroid resistance are now better understood, and this has identified new targets for therapy. In patients with severe asthma, several molecular mechanisms have been identified that might account for reduced steroid responsiveness, including reduced nuclear translocation of glucocorticoid receptor (GR) ?? after binding corticosteroids. This might be due to modification of the GR by means of phosphorylation as a result of activation of several kinases (p38 mitogen-activated protein kinase ??, p38 mitogen-activated protein kinase ??, and c-Jun N-terminal kinase 1), which in turn might be due to reduced activity and expression of phosphatases, such as mitogen-activated protein kinase phosphatase 1 and protein phosphatase A2. Other mechanisms proposed include increased expression of GR??, which competes with and thus inhibits activated GR??; increased secretion of macrophage migration inhibitory factor; competition with the transcription factor activator protein 1; and reduced expression of histone deacetylase (HDAC) 2. HDAC2 appears to mediate the action of steroids to switch off activated inflammatory genes, but in patients with COPD, patients with severe asthma, and smokers with asthma, HDAC2 activity and expression are reduced by oxidative stress through activation of phosphoinositide 3-kinase ??. Strategies for managing steroid resistance include alternative anti-inflammatory drugs, but a novel approach is to reverse steroid resistance by increasing HDAC2 expression, which can be achieved with theophylline and phosphoinositide 3-kinase ?? inhibitors. Long-acting ??2-agonists can also increase steroid responsiveness by reversing GR?? phosphorylation. Identifying the molecular mechanisms of steroid resistance in asthmatic patients and patients with COPD can thus lead to more effective anti-inflammatory treatments. ? 2013 American Academy of Allergy, Asthma & Immunology.
机译:对皮质类固醇抗炎作用的反应性降低是吸烟者和重度哮喘患者以及大多数慢性阻塞性肺疾病(COPD)患者有效控制哮喘的主要障碍。现在,人们对导致类固醇抵抗的分子机制有了更好的了解,这已经确定了治疗的新目标。在患有严重哮喘的患者中,已经确定了几种可能导致类固醇反应性降低的分子机制,包括糖皮质激素受体(GR)的核转运降低。结合皮质类固醇后。这可能是由于几种激酶(p38丝裂原活化的蛋白激酶,p38丝裂原活化的蛋白激酶,c-Jun N端激酶1)激活而通过磷酸化修饰了GR。 ,这可能是由于磷酸酶(例如有丝分裂原激活的蛋白激酶磷酸酶1和蛋白磷酸酶A2)的活性和表达降低所致。提出的其他机制包括增加与细胞竞争并因此抑制活化的GR 17的GR 12表达。巨噬细胞迁移抑制因子的分泌增加;与转录因子激活蛋白1竞争;并降低组蛋白脱乙酰基酶(HDAC)2的表达。HDAC2似乎介导类固醇关闭已激活的炎症基因的作用,但在COPD,重度哮喘和吸烟者中,HDAC2的活性和表达会因氧化而降低通过激活磷酸肌醇3-激酶来缓解应激。控制类固醇耐药性的策略包括替代性抗炎药,但一种新方法是通过增加HDAC2表达来逆转类固醇耐药性,这可以通过茶碱和磷酸肌醇3激酶实现。抑制剂。长效β2-激动剂也可通过逆转GRβ来增加类固醇反应性。磷酸化。因此,确定哮喘患者和COPD患者中类固醇抵抗的分子机制可以导致更有效的抗炎治疗。 ? 2013年美国过敏,哮喘和免疫学学会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号